Kornimate/medical-research-clean huggingface dataset:
parent training to promote early identification and treatment of childhood behavioral disorders

Conditions: Attention Deficit Disorder With Hyperactivity; Attention Deficit and Disruptive Behavior Disorders

Summary: this study will evaluate the effectiveness of a parent training program in improving parenting skills and reducing behavioral symptoms in young children who are at risk for developing childhood behavior disorders.

attention deficit hyperactivity disorder (adhd) and oppositional defiant disorder (odd) are common childhood behavior disorders. children with adhd experience hyperactivity, distractibility, poor concentration, and impulsivity. if left untreated, adhd can continue into adulthood, and can cause problems in family, social, and work environments. children with odd exhibit an ongoing pattern of uncooperative, defiant, and hostile behavior toward authority figures. symptoms of odd, including frequent temper tantrums, anger, resentment, and vindictiveness, may interfere with a child's everyday functioning. the incredible years parent training program has been shown to be effective in multiple settings at training parents to manage their child's behavior. this study will evaluate the effectiveness of the incredible years training program within a pediatric office setting at improving parenting skills and reducing behavioral symptoms in young children who are at risk for developing childhood behavior disorders. participants in this open-label study will be randomly assigned to the incredible years training program or a waitlist condition, in which they will begin the program after a 1-year waiting period. parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs. self-report assessments and phone interviews will be used to assess outcomes. additionally, follow-up visits will occur immediately post-intervention and 6 and 12 months post-intervention. children will attend one visit before the program begins, as well as the follow-ups held immediately post-intervention and 12 months post-intervention. these visits will include videotaped observations of children and their primary caregivers.

Eligibility criteria:
inclusion criteria: parent or primary caregiver of a child who fits the following criteria: * receives a positive result on behavioral screening exclusion criteria: parent or primary caregiver of a child who fits the following criteria: * diagnosis of pervasive developmental disorder or global developmental delay

Keywords: parenting education child, preschool preventive intervention primary health care pediatrics attention deficit disorders oppositional defiant disorder disruptive behavior disorder
early shockwave therapy for post-rp ed

Conditions: Erectile Dysfunction Following Radical Prostatectomy

Summary: this pilot study aims to explore the feasibility, safety and effectiveness of two different extracorporeal shock wave therapy (eswt) protocols for patients receiving nerve-sparing radical prostatectomy (rp).

this is an open-label, randomized, 2-parallel-arm trial (n=94). all patients will receive (a) sham (n=47) or (b) active eswt (n=47) twice/week for 6 weeks (12 sessions total). concurrently, all patients will receive daily tadalafil 5mg for 24 weeks. patients will then undergo a 4 week washout period without erectogenic aids, and return for a 28-week evaluation. subsequently, patients requiring further erectogenic aids after 28 weeks will be offered intracavernosal injections (ici) of prostaglandin e1 (pge1). random assignment will be performed by computer program (eg. randomizer.org), in a design that obtains equal sample size per group. all patients will be followed for a period of 24 months post-rp. follow-up protocol includes evaluation of the iief, ehs, gaq, ici usage and tolerability, stretched flaccid penile length, urinary incontinence, and oncologic status.

Eligibility criteria:
inclusion criteria: * men scheduled for robotic bilateral nerve-sparing radical prostatectomy * diagnosed with low/intermediate-risk prostate cancer: * psa \< 20 ng/ml * gleason score \< 8 * pca stage =\< t2b * baseline iief-ed 22-30 without erectogenic aids * no urinary incontinence (no usage of urinary pads) * sexually active, in a stable heterosexual relationship * able to understand and complete patient questionnaires * consent to participate exclusion criteria: * anatomical abnormalities in the genitalia or pelvic region * post-rp complications that could impact safety or effectiveness of eswt (eg. hematoma, fistula, unresolved anastomotic leak) * incomplete tumor removal (positive surgical margin) * tumor upstaging beyond t2b * nerve sparing score \< 4 * previous or scheduled treatment with pelvic radiotherapy and/or androgen deprivation therapy * untreated hypogonadism (serum total testosterone \< 300 mg/dl) * anti-coagulant medication, or any blood coagulation disorders (inr \> 3) * any other condition that would prevent the patient from completing the study, as judged by the principle investigator
bupivacaine liposomal injectable suspension, pain and narcotic use after elective orthognathic surgery

Conditions: Orthognathic Surgery

Summary: this research is being done to determine quantitative and qualitative differences in patients' post-operative pain levels following elective orthognathic surgery after the local administration of a liposomal bupivacaine injection. a primary objective is to determine whether using a liposomal bupivacaine injection placed locally at the conclusion of elective orthognathic surgery will decrease pain levels (as determined by vas scores). a secondary objective is to examine whether using a long acting liposomal bupivacaine injection locally at the conclusion of elective orthognathic surgery leads to decreased use of narcotics post-operatively.

participants in group 1 (study group) will receive expareltm (133 mg/10 ml - 4 ml into the maxilla, and 6 ml into the mandible). this will be injected into the soft tissue and gingiva surrounding the surgical site at the time of wound closure. participants in group 2 (standard of care) will receive bupivacaine 0.5% (4 ml into the maxilla, and 6 ml into the mandible) injected into the soft tissue and gingiva surrounding the surgical site at the time of wound closure. post-operatively, all participants will be cared for utilizing the current standard post-operative pain management protocol for all patients undergoing elective orthognathic surgery at boston medical center. this consists of acetaminophen 325 mg given every 4 hours as a scheduled medication; patients also receive an additional 325 mg of acetaminophen for a reported pain level of 1-3, 5 mg of oxycodone for a reported pain level of 4-6, and 10 mg of oxycodone for a reported pain level of 7-10. all participants will be provided the same methods of postoperative pain control following their elective orthognathic surgery.

Eligibility criteria:
inclusion criteria: * males and females 18-40 years of age undergoing elective double jaw orthognathic surgery exclusion criteria: * pregnancy * known hypersensitivity to any local anesthetic

Keywords: bupivacaine liposomal injectable post operative pain post operative narcotic use bupivacaine hydrochloride
epileptogenic network visualisation with advanced mri

Conditions: Drug Resistant Epilepsy

Summary: the goal of this clinical trial is to improve non-invasive identification of epileptogenic networks in drug-resistant epileptic patient. the investigators aim to compare epileptogenic network identification with stereo-eeg (used as glod standard) with the identification of the same network using advanced mri (rs-fmri, microstructural analysis of white matter, ...). the main goals are to: 1. compare the accuracy of network identification. 2. analyse the effect of the mri sequences on candidates selection and target identification. participants will already have been selected for stereoeeg and will undergo a supplementary mri (about 1h) with the additional mri sequences. follow-up mri are scheduled for patient undergoing a second, therapeutic epileptic surgery.

patient identified for seeg will undergo, prior to the implantation procedure an mri with the following sequences: * 3d t1 * rsfmri * multishell diffusion the rsfmri will be post-processed to delineate the epileptogenic networks based on an independant component analysis (ica) methods. once the epileptogenic network(s) has/have been identified, connexion between the different regions will be identified through post-processing of the diffusion using a msmt-csd algorithm. finally, the identified tract between the different region will be quantitatively analysed using different algorithms (noddi, diamond, mf) to better grasp there integrity. in a follow-up study, the patients that will later on benefit from a resection or disconnection (i.e. curative surgery) will also have an identical mri 3 months after the said procedure to evaluate the evolution on the network(s) based on the same criteria.

Eligibility criteria:
inclusion criteria: * patient suffering from drug-resistant epilepsy * patient already selected for seeg implantation as part of their epileptic networks exclusion criteria: * patient excluded from seeg (pregnant women, children too young for the procedure, patient unable to undergo the procedure) * contra-indication for mri

Keywords: epilepsy network non-invasive investigation
modified polyurethane film dressing for skin graft donor sites

Conditions: Wound Healing

Summary: the purpose of this study is to determine whether the combination of modified polyurethane film and secondary absorbent dressing for skin graft donor sites avoids the regular uncontrolled leakage, but holds up the advantages of film dressings for this kind of wound.


Eligibility criteria:
inclusion criteria: * adults over age 18 who require skin grafting exclusion criteria: * individuals under the age of 18.

Keywords: healing time pain infection
efficacy and safety of zolmitriptan by sublingual administration

Conditions: Cluster Headache

Summary: the purpose is to evaluate the effectiveness and safety profile of zolmitriptan by sublingual administration for the acute treatment of cluster headache.

cluster headache is a primary neurological disorder characterized by intensive attacks and severe sharp headache, can cause a range of symptoms such as conjunctival congestion, runny nose, miosis, forehead sweat. the disability resulting from cluster headache can be severe imposing a considerable health burden upon the sufferer and society. the purpose of this study, using oral zolmitriptan as the control, is to evaluate the effectiveness and safety of zolmitriptan by sublingual administration for the acute treatment of cluster headache. patients are asked to maintain a headache diary throughout the treatment period.

Eligibility criteria:
inclusion criteria: * patients older than or equal to 18 years and less than 70 years; * the diagnosis of cluster headache is made according to the international classification of headache disorders: 3rd edition (beta version)(ichd-iii β); * consent form signed by the participant or his/her authorized surrogate. exclusion criteria: * patients had primary or secondary headache disorders other than cluster headache; * female subjects of childbearing age will be excluded if they were pregnant, lactating or planning a pregnancy in the next year or if they were not using an adequate form of birth control; * patients will be excluded if they had significant medical or psychiatric disease; * patients will be excluded if they had coronary heart disease or not suitable for the treatment of zolmitriptan.

Keywords: cluster headache zolmitriptan sublingual administration
addition of silver nanoparticles to a orthodontic primer in preventing enamel demineralization adjacent brackets

Conditions: Tooth Demineralization

Summary: evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic transbond xt in preventing enamel demineralization adjacent to brackets.

randomized, split mouth, double-blind, placebo controlled trial. half of the mouth was applied silver nanoparticles incorporated into the primer orthodontic transbond xt and the other half with primer-bond as placebo. evaluate the effectiveness with diagnodent - pen in preventing enamel demineralization adjacent to brackets.

Eligibility criteria:
inclusion criteria: * patients candidates for orthodontic treatment. exclusion criteria: * patients with o.d 11 and / or 21 absent. * patients who present dentures of any kind in od 11 and 21. * patients presenting endodontic od 11 and 21. * patients presenting data gingivitis day cementing brackets.

Keywords: silver nanoparticles demineralization brackets
proof of concept study to assess the efficacy, safety of hrs-5965 in patients with paroxysmal nocturnal hemoglobinuria

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Summary: this is a multicenter, randomized, open-label phase ii clinical trial. a total of 24 patients with paroxysmal nocturnal hemoglobinuria naïve to complement inhibitor therapy were included. subjects were treated with hrs-5965 for 12 weeks.


Eligibility criteria:
inclusion criteria: 1. diagnosis of pnh confirmed by flow cytometry with clone size ≥ 10%. 2. have not received complement inhibitor therapy ; 3. ldh \> 1.5×uln; 4. hemoglobin level \< 10 g/dl. exclusion criteria: 1. known or suspected hereditary or acquired complement deficiency; 2. patients with laboratory evidence of bone marrow failure (reticulocytes \<100x109/l; platelets \<30x109/l; neutrophils \<0.5x109/l); 3. presence or suspicion of a systemic active bacterial, viral, or fungal infection (based on judgment of the investigator) within 2 weeks prior to the first dose of hrs-5965; 4. history of infection with capsular bacteria (e.g., meningococcus, pneumococcus, etc.) 5. positive of hiv, hbsag or hcvab.
fractures stratified by hiv and antiretroviral therapy (art) status

Conditions: Fracture; Infection, Human Immunodeficiency Virus

Summary: this us population-based study will explore the incidence of and risks for fracture among adults with and without human immunodeficiency virus (hiv) infection. the objectives are to determine the incidence of fracture among persons with and without hiv infection, compare risk factors for fracture among persons with and without hiv infection, and to examine the associations of antiretroviral (arv) treatment exposure for incidence and risk of fracture among persons with hiv infection.

this study uses data from the integrated health care information services (ihcis) national managed care benchmarked database, a health insurance claims database. the study has two analytic components. the first is a retrospective cohort study comparing subjects without hiv infection to subjects with hiv infection for the incidence of and risk for fracture, including the use of anyarv drugs in persons with hiv infection. the second is a nested case-control study limited to persons with hiv infectiion within the cohort. cases are those with incident fractures occurring after the diagnosis of hiv infection, and controls those without a fracture. cases and controls will be compared for risk factors for incident fracture including arv drug exposure. the drug exposures will include individual nucleoside reverse transcriptase inhibitors (nrtis) (as permitted by sample size) and the other arv drug classes. viiv healthcare is the new sponsor of this study, and glaxosmithkline is in the process of updating systems to reflect the change in sponsorship.

Eligibility criteria:
inclusion criteria: * the inclusion criteria was continuous enrollment for at least 12 months in the integrated health care information services (ihcis) national managed care benchmarked database during the interval between january 1, 1997 and march 31, 2008, age 18 years of age and older, and continuous eligibility for pharmacy benefits during ihcis enrollment. exclusion criteria: * exclusion criteria were membership in the integrated health care information services (ihcis) national managed care benchmarked database without a valid gender or age record, less than 12 months continuous enrolment, and member residence in the 'national' census region. this latter grouping represented members who were either not living in the continental us or were masked for confidentiality reasons based on ihcis archiving of data per the health insurance portability and accountability act.

Keywords: combivir (zidovudine+lamivudine) trizivir (abacavir+lamivudine+zidovudine) zidovudine epzicom (abacavir+lamivudine) fracture amprenavir human immunodeficiency virus (hiv) infection antiretroviral (arv) therapy lamivudine incidence abacavir risk fosamprenavir
transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukaemia

Conditions: Acute Myeloid Leukaemia

Summary: acute myeloid leukaemia (aml) is a haematological malignant disease characterized by an uncontrolled proliferation of immature hematopoietic cells. over the last two decades, clinical trials have demonstrated an improved response rate in younger adult aml. aggressive induction plus more potent intensification programs with chemotherapy alone or chemotherapy plus stem cell transplantation (sct) has improved treatment results. advances in understanding disease biology, improvements in induction and consolidation program, and better supportive care have also all contributed. a number of clinical and laboratory characteristics influence the response to treatment and, thus, the survival of patients with aml. among them, cytogenetic at diagnosis represents the most important prognostic variable. however, other factors may have a prognostic value and may influence patient's outcome. anaemia and thrombocytopenia are cardinal manifestations of aml. over the last decades, it has become apparent that the frequency of allogeneic blood transfusions can modify host immunity and clinical outcomes. anaemia has long been recognized as an adverse prognostic factor in myelodysplastic syndrome (mds), which represents a pre-leukemic disease. red blood cell (rbc) transfusion need was identified as a strong and independent risk factor for survival in mds, for which the presence and severity of anaemia were attributed to a clonally advanced and biologically more aggressive disease. based on these data, the investigators retrospectively assessed the prognostic value of rbc and platelet transfusions at the time of diagnosis and the frequency of transfusions during the first induction course of chemotherapy in a large unselected group of patients with previously untreated aml.


Eligibility criteria:
inclusion criteria: * patient \> 15 years old * newly diagnosed aml or post myelodysplastic syndrome (mds) exclusion criteria: * patients with m3 aml of french-american-british (fab) classification (apl, acute promyelocytic leukemia) * world health organization (who) performance status \>2; (ii) * left ventricular systolic ejection fraction below the normal range * patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study * serum creatinine concentration \> 2x uln (upper limit of normal laboratory ranges), * ast or alt levels \> 2.0 x upper limit of normal (uln), except if aml-related

Keywords: acute myeloid leukaemia transfusion dependency transfusion intensity prognosis chemotherapy
safety and efficacy of shenyankangfu tablets for chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: safety and efficacy of long-term application of shenyankangfu tablets in large sample of patients with chronic kidney disease.

research purpose: safety and efficacy of long-term application of shenyankangfu tablets in large sample of patients with chronic kidney disease. the crowd: patients with primary glomerular nephritis, diabetic nephropathy patients. study design: a multicenter clinical study design, openness. the study drug: shenyan kangfu tablets. statistical analysis: research plan is determined, by statistical professionals responsible for negotiation with the principal investigator for statistical analysis plan.

Eligibility criteria:
inclusion criteria: 1. diagnosed with primary glomerulonephritis or diabetic nephropathy; 2. aged from 18 to 70 years，male or female 3. gfr≥45ml/min/1.73㎡ 4. 0.5g≤24 hours proteinuria≤3.0g 5. glycated hemoglobin (hbalc) ≤8% (this has been limited to patients with diabetic nephropathy) 6. traditional chinese medicine syndrome conform qi-yin deficiency 7. obtain the agreement of patients or their guardians, and signed informed consent file exclusion criteria: 1. secondary nephropathy 2. people allergic to shenyankangfu tables 3. combined with severe primary disease of heart, brain, liver and hematopoietic system, or other serious diseases can affect patient's life 4. pregnant or lactating women 5. be participating in another clinical study at the same period
electrophysiological activity of the anorectum in children suspected of hirschsprung disease

Conditions: Hirschsprungs Disease

Summary: children with chronic constipation, suspected of having hirschsprungs disease, who are admitted for rectal biopsy will be included in the study. during the procedure, electrophysiological reading from the site chosen for biopsy will be done. correlation between electrophysiological data and histopathology will be analyzed.

hirschsprungs disease is found in 1:5000 newborns, the disease is caused by aganglionosis of the colon, leading to severe constipation and possible bowel obstruction. the diagnosis is based on leveling biopsies taken from the rectum and colon. treatment is supportive if complications had arisen, and surgical for definitive correction of the pathophysiological condition which is the cause of the disease. currently, clinicians rely on histopathology, for diagnosing the disease, and planning surgical correction. the main goal of surgical treatment will be the creation of a continuous patent and innervated bowel, in which effective propulsive peristalsis is taking place. this is achieved by resection of aganglionic colon, and anastomosis of normal colon with normal ganglia, to anus. today surgeons await histopathology report for the diagnosis of hirschsprungs disease, and frozen section biopsies taken when in surgery to ascertain the level of ganglionated bowel. in this study the investigators aim to correlate electrophysiological reading, from colon suspected of hirschsprungs disease. if correlation is found, or a specific pattern which is diagnostic of the disease may be found, the electrophysiological study may offer a new way of diagnosing the disease, which is not invasive and allows prompt diagnosis in contrast to histopathology which is time consuming. a reliable electrophysiological study for hirschsprungs disease may be helpful in early and correct diagnosis, with a noninvasive procedure as compared to a biopsy of the colonic wall. children with chronic constipation, suspected of having hirschsprungs disease, who are admitted for rectal biopsy will be included in the study. during the procedure, electrophysiological reading from the site chosen for biopsy will be done. correlation between electrophysiological data and histopathology will be analyzed. the actual reading will be carried out by a custom made electrode by gaeltec devices ltd : dunvegan : isle of skye : scotland.

Eligibility criteria:
inclusion criteria: * patient admitted for rectal biopsy, by clinical decision, so that hirschsprungs disease may be diagnosed or ruled out exclusion criteria: none -